Please try another search
For the nine months ended 30 September 2019, Fibrocell Science Inc revenues increased from $0K to $22.8M. Net income applicable to common stockholders totaled $178K vs. loss of $9.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Other income (expense), net increase from $227K to $515K (income).
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 1.02 | 21.79 | 0 | 0 |
Gross Profit | -0.67 | 16.62 | ||
Operating Income | -4.36 | 13.57 | -3.86 | -3.23 |
Net Income | -7.2 | 11.74 | -3.67 | -1.62 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 27.83 | 34.86 | 18.14 | 15.76 |
Total Liabilities | 17.09 | 16.99 | 12.13 | 6.2 |
Total Equity | 10.74 | 17.86 | 6 | 9.56 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -7.29 | -0.65 | -3.08 | -12.72 |
Cash From Investing Activities | -0.34 | -0.09 | -0.01 | -0.16 |
Cash From Financing Activities | -0.04 | -0.02 | -0.02 | 9.89 |
Net Change in Cash | -7.66 | -0.76 | -3.11 | -2.99 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review